Targeting ncca-atp channel for organ protection following ischemic episode
AssigneeUniversity of Maryland, Baltimore
InventorJ. Marc Simard
Life of this patent
Estimating the term…
Abstract
The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example
Claims33
A method of preventing or reducing ischemic damage in one or more organs or tissues, comprising delivering to the individual an effective amount of an inhibitor of an NCCa-ATP channel in a pharmaceutically acceptable carrier.
A method of determining the amount or severity of ischemic damage in one or more organs or tissues following an ischemic episode in an individual, comprising assaying one or more cells of the respective organ or tissue for a NCCa-ATP channel.
A kit comprising an inhibitor of NCCa-ATP channel and an organ transplant therapeutic compound;
- and/or an organ transplantation apparatus, each of which is housed in a suitable container:
Dependencies are inferred from the claim text.